Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (22,686,271)	$ (4,318,742)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation - services	207,143	45,615
Stock based compensation - prepaid	900,560	713,537
Stock issued for amending convertible promissory notes	320,850
Gain from settlement on accounts payable	(15,000)
Gain from deconsolidation of Oak Therapeutics, Inc	(80,868)
Change in fair value of contingent stock consideration	8,520,000
Loss on conversion of convertible promissory notes	3,659,518
Warrant expense from convertible notes	2,173,056
Depreciation and amortization	267,143	72,164
Amortization of loan discounts	1,163,900	519,716
Recovery of bad debt expense	(7,500)
Inventory reserve for obsolesce	3,752
Change of fair value in derivative liabilities	(273,003)	(206,387)
Fair value of vested stock options and restricted shares	888,938	461,268
Warrants granted for commission expense	1,268,010	94,277
Warrants granted for broker fee expense	410,770
Cashless exercise of warrants
Change in other assets and liabilities:
Accounts receivable	(45,764)	(61,801)
Inventory	(15,295)	(54,831)
Prepaid expenses and other assets	(93,957)	153,705
Other assets	23,740	16,970
Accounts payable	(495,238)	106,311
Accrued expenses	(676,253)	144,350
Deferred revenue	(65,192)	46,801
License fees	95,000
Cash used in operating activities	(4,551,962)	(2,267,047)
Cash flows from investing activities
Purchase in intangible assets	(29,143)	(47,632)
Proceeds from common stock issuance for acquisition of Chemistry Holdings, Inc	8,487,490
Acquisition of property and equipment, net	(790,022)	(23,417)
Cash provided by (used in) investing activities	7,668,325	(71,049)
Cash flows from financing activities
Proceeds from convertible notes payable	3,425,000	2,775,000
Proceeds from common stock issuance	750,000
Proceeds from stock payable	1,745,000
Proceeds from exercise of warrants	60,480
Repayment of convertible notes payable	(1,225,000)
Repayment of notes payable	(650,000)
Repayment of loans payable	(78,195)	(384,102)
Cash provided by financing activities	4,027,285	2,390,898
Net increase in cash and cash equivalents	7,143,648	52,802
Cash and cash equivalents, beginning of period	500,962	108,249
Cash and cash equivalents, end of period	7,644,610	161,051
Cash paid for interest and income taxes:
Interest	89,529	33,359
Income taxes
Non-cash financing activities:
Common stock related to prepaid expenses	658,723	1,041,114
Warrants granted for discount on convertible promissory notes		567,385
Beneficial conversion features for convertible promissory notes	801,331
Common stock issued for conversion of promissory notes and accrued interest	8,623,628
Common stock payable for note conversion	938,261
Common stock issued for settlement of accounts payable	64,520
Fixed assets received from the acquisition of Chemistry Holdings, Inc	82,700
Patents received from the acquisition of Chemistry Holdings, Inc	650,000
In-process research and development received from the acquisition of Chemistry Holdings, Inc	14,460,000
Goodwill resulting from the acquisition of Chemistry Holdings, Inc	9,178,477
Contingent share considerations for acquisition of Chemistry Holdings, Inc	14,632,000
Liabilities assumed from the acquisition of Chemistry Holdings, Inc	1,188,667
Convertible promissory note payable eliminated from the acquisition of Chemistry Holdings, Inc	2,000,000
Cashless exercise of warrants	26
Liabilities released as a result of deconsolidation of Oak Therapeutics, Inc	75,590
Non-controlling interest released as a result of deconsolidation of Oak Therapeutics, Inc	$ 5,914